Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Imunon Inc IMNN

Healthcare Biotechnology

Imunon, Inc. is a clinical-stage biotechnology company. The Company is focused on advancing a portfolio of treatments that harness the body’s natural mechanisms across an array of human diseases. The Company is developing non-viral Deoxyribonucleic acid (DNA) technology across four modalities. The first modality, TheraPlas, is developed for the coding of proteins and cytokines in the treatment... see more

Add To Watchlist

Recent & Breaking News (NDAQ:IMNN)

Celsion Corporation and myTomorrows Partner to Introduce ThermoDox® Early Access Program in Europe for Patients with Recurrent Chest Wall Breast Cancer

PR Newswire January 20, 2015

Celsion Corporation Submits DNA-based Immunotherapy Clinical Protocol to the FDA as Part of a First Line Treatment for Ovarian Cancer

PR Newswire January 6, 2015

Celsion Corporation Reports Third Quarter 2014 Financial Results

PR Newswire November 11, 2014

Celsion Corporation Receives VHP Approval to Initiate OPTIMA Study in Europe

PR Newswire November 5, 2014

Celsion Corporation to Hold Third Quarter 2014 Financial Results Conference Call on Tuesday, November 11, 2014

PR Newswire November 4, 2014

Celsion Presents Preclinical Data for its TheraSilence(TM) Platform at the miRNA World Conference Workshop on miRNA Delivery

PR Newswire October 29, 2014

Celsion Announces Appointment of Michael H. Tardugno to Executive Chairman of the Board of Directors

PR Newswire October 7, 2014

Celsion Announces The Unexpected Passing of Max E. Link, Ph.D., Chairman of the Board

PR Newswire October 7, 2014

INVESTOR ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Celsion Corp. Regarding Possible Breaches of Fiduciary Duty

PR Newswire September 17, 2014

Celsion Announces Highlights from Three Presentations Given at the International Liver Cancer Association 2014 Annual Conference

PR Newswire September 8, 2014

Celsion Reports Consolidated Duke University and Celsion's DIGNITY Study Clinical Data on ThermoDox® in Recurrent Chest Wall Breast Cancer Published in the International Journal of Hyperthermia

PR Newswire September 4, 2014

Celsion Announces Enrollment of First Patient in Global Phase III OPTIMA Study of ThermoDox® in Primary Liver Cancer

PR Newswire September 2, 2014

Celsion to Present at the Rodman & Renshaw 16th Annual Healthcare Conference

PR Newswire August 28, 2014

Celsion Corporation Reports Second Quarter 2014 Financial Results

PR Newswire August 7, 2014

Celsion Corporation to Hold Second Quarter 2014 Financial Results

PR Newswire July 31, 2014

Celsion Announces Updated Overall Survival Data from HEAT Study of ThermoDox® in Primary Liver Cancer

PR Newswire July 28, 2014

Celsion Announces Positive Interim Data Update from its Phase 2 DIGNITY Study in Breast Cancer

PR Newswire July 24, 2014

Celsion Corporation Announces $1 Million NIH, NIBIB - Career Development Award Grant for Glioblastoma Research with ThermoDox® and HIFU

PR Newswire July 21, 2014

Celsion Corporation (NASDAQ: CLSN) to Ring The NASDAQ Stock Market Closing Bell

GlobeNewswire July 15, 2014

Celsion Corporation Announces Commercialization of Reagent Products

PR Newswire July 15, 2014